Navigation Links
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
Date:5/6/2009

nant melanoma, multiple myeloma, glioblastoma and sarcoma. AXL1717, orally administered, is being developed as a new type of anti-cancer drug.

About Cancer, the IGF-1 receptor and AXL1717

Globally more than 12 million people are diagnosed with cancer every year. Cancer causes the death of about 8 million people per year. Although a number of cancer drugs have successfully been launched over the last decade, many cancers still lack an effective therapy. This, together with the fact that many treatments result in severe side effects, highlights the strong medical need for new and alternative anti-cancer therapies.

About Axelar AB

Axelar AB is a Swedish biotech company founded in 2003 and based on research performed at the Karolinska Institute, Stockholm, Sweden. The company focuses its activities on research related to IGF-1 receptor inhibitors and their applications in different important human diseases such as cancer, psoriasis, atherosclerosis and restenosis after angioplasty. The business strategy is to outlicense projects after successful clinical trials.

For more information, please contact:

Johan Harmenberg, MD, PhD (CEO Axelar AB)

Telephone: +46-705-14-54-53 or visit http://www.axelar.se


'/>"/>
SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
4. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
5. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
6. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
7. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
8. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
9. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
10. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
11. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MX (PRWEB) September 18, 2014 September ... Mexico City, MX. ASEA is the manufacturer of the ... the skin care product, RENU28. , The Mexico ... Vice President Duvan Botero, and ASEA Field Leader Shawn ... holds a PhD in Atomic/Medical Physics from the University ...
(Date:9/17/2014)... INCLINE VILLAGE, Nev. , Sept. 17, 2014  PDL ... notified by its independent registered accounting firm, Ernst & Young ... The resignation was confirmed in a letter delivered to the ... 8-K filed on September 16, 2014.  PDL ... "We have received a number of inquiries on ...
(Date:9/17/2014)... -- The global consumption of squalene / squalane is expected ... skin-identical chemical that finds applications in various end user industries ... in other applications like high grade lubrication, and fiber coating ... players and is regionally segregated. Sophim ( France ... ( Japan ), SeaDragon Marine Oils Ltd. ( ...
(Date:9/17/2014)... , Sept. 17, 2014  The In Silico ... that will be featured at the conference, which takes ... on December 3 and 4, 2014. Researchers, students, drug ... to hear the following: KEYNOTE SPEAKERS ... Diego Skaggs School of Pharmacy Drug ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7
... Amgen (Nasdaq: AMGN ) today announced that ... financial results on Monday, Jan. 24, 2011 after the close ... a conference call with the investment community at 2:00 p.m. ... Kevin Sharer, chairman and chief executive officer, and other members ...
... 2011 Sensus Healthcare is pleased to ... professional skin care products to be exclusively offered by ... Cases of skin cancer are on the rise and ... taking new aim at skin cancer (SM) in ...
... 2011 Cephalon, Inc., (Nasdaq: CEPH ) will hold ... founder and late Chairman and CEO on February 1, 2011, at ... Street, Philadelphia, Pennsylvania. Dr. Baldino founded Cephalon in ... one of the top ten biotechnology companies in the world. He ...
Cached Biology Technology:Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results 2Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™ 2Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D. 2
(Date:9/18/2014)... invisible is probably the ultimate form of camouflage: you ... And this strategy is not as uncommon as you ... Baltimore County, USA, explains that the larval life stages ... one part of the anatomy that most creatures cannot ... eyes have to shield each individual eye unit with ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... genetic disorder known as Jacobsen syndrome has been linked ... researchers at San Diego State University and the University ... treatment options for people with Jacobsen syndrome, the finding ... autism., Jacobsen syndrome affects approximately 1 in 100,000 people, ... in a person when there is a deletion at ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
... is difficult to measure accurately each nation,s contribution of carbon ... the ground as coal, gas, and oil, and these fuels ... to generate the energy that is used to make products. ... countries where they are consumed. A team led by Carnegie,s ...
... The University of Texas at Austin whose technology developments in ... tens of thousands of patients with diseases such as cancer ... Institute of Medicine (IOM). Established in 1970, IOM is ... institute is considered one of the highest honors in health ...
... of spinal cord injury is receiving attention in the ... the department of biomedical engineering at NJIT, recently has ... micro-electrical stimulators for individuals with spinal cord injuries. ... year of support from a four-year, $1.4 million National ...
Cached Biology News:Links in the chain: Global carbon emissions and consumption 2UT professor elected to the Institute of Medicine of the National Academies 2UT professor elected to the Institute of Medicine of the National Academies 3NJIT researcher testing micro-electronic stimulators for spinal cord injuries 2
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Tachykinin (H-2)...
...
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
Biology Products: